Seeking Alpha

Regeneron (REGN +5.8%) gains after blowing away Q3 estimates earlier this morning. Total...

Regeneron (REGN +5.8%) gains after blowing away Q3 estimates earlier this morning. Total revenues soared over 300% Y/Y on strong demand for Eylea, REGN's injection for the treatment of neovascular age-related macular degeneration. Sales of the drug were up 26% from 2Q. The company boost its sales estimates again for the year, and notes that Eylea should further fuel growth in 2013 following recent FDA approval for its expanded use.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector